A recent study looking at data from three clinical trials involving Nerlynx shows promise for the future of treating patients with HER-2 positive breast cancer who develop CNS metastases.
Nancy Lin, M.D.
Advertisement
Articles by Nancy Lin, M.D.
Advertisement
Latest Updated Articles
Novel HER-2 Targeted Agents Show Promise in Treating CNS MetastasesPublished: February 21st 2020 | Updated:
Advertisement
Advertisement
Trending on CURE
1
Peritoneal Mesothelioma Survivor Shares Ongoing Reality of Survivorship
2
What Does a Stage 2 Prostate Cancer Diagnosis Mean for Me?
3
SUNRiSE-1 Participant Shares Insights on Bladder Cancer Education
4
Becoming Cancer-Aware: How My Diagnosis Changed the Way My Family Sees Everyday Products
5
